PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA for orphan drug designation as it works to further study the uses of ketamine. The latest filing pertains to the use of ketamine to treat Lou Gehrig’s disease, which is formally known as ALS, or amyotrophic lateral sclerosis.

Lou Gehrig’s disease is a neuromuscular disease, which currently has a life expectancy of just two to six years after initial diagnosis. The disease effectively causes upper and lower motor neurons to die, causing the brain to lose function of muscle movement. As the disease progresses patients lose voluntary muscle action, causing the inability to speak, eat, move and breathe. There is currently no cure for the disease.

Initial research conducted on ketamine has indicated that it has the potential to increase life expectancy of those impacted by the disease, slowing the progressive loss of muscle. Preclinical work has demonstrated that the compound preserves muscle function in advancing ALS, and improves life expectancy when administered early in the stages of muscles decline.

“Ketamine has tremendous potential for not only mental illness and pain disorders but also for neurodegenerative diseases such as ALS.  Our FDA orphan drug application for ketamine to treat this life-threatening disease complements our patent portfolio that aims to protect the proposed method of use and dosage claims of ketamine for ALS.  Although patent protection or market exclusivity could last beyond 2040, our intention to seek orphan drug designation is to leverage the expedited regulatory and clinical development incentives offered by the FDA for repurposed drugs in treating rare diseases.”

Fabio Chianelli, Chief Executive Officer of PharmaTher

PharmaTher Holdings last traded at $0.40 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Gold’s Wild Bull Run: Are Markets About to Break? | Mike McGlone

First Majestic Silver: The Santa Elena Mine

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM

PharmaTher To Develop Digital Therapeutics Platform Focused On Psychedelic Therapies

Pharmather Inc (CSE: PHRM) this morning announced that it has amended its sponsored research agreement...

Tuesday, December 1, 2020, 07:36:07 AM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM

PharmaTher Partners With TSRL For Microneedle Patch Development

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The...

Tuesday, June 1, 2021, 08:21:51 AM

PharmaTher Secures Japanese Patent For Ketabet

PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its...

Tuesday, November 30, 2021, 09:52:00 AM